Arun Azad

Oncology — Peter MacCallum Cancer Centre, Australia

LeadR Profile

2 146 ScienceLeadR Reputation 2146
Network Map

Oncology

Subspecialties: Urology - Nuclear Medicine - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026

Source: PubMed

Peter MacCallum Cancer Centre

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 421

Citations

Citations: 12 926 1st author: 73 Last author: 82 Unique author: 6


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial.
growth, insulin, docetaxel, somatomedins, neoplasms, prostate, drug therapy, biomarkers, hormones, prostatic neoplasms, therapeutics, prognosis, plasma, chemotherapy
Prostate20260
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
cells, progression-free survival, disease progression, carcinoma, renal cell, drug-related side effects and adverse reactions, therapeutics
Lancet Top journal20263
Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer.
research design, genes, recombination, genetic, homologous recombination, neoplasms, prostate, hormones, recombinational dna repair, prostatic neoplasms, therapeutics, mutation
Asia Pac J Clin Oncol20260
Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.
cells, neoplasms, carcinoma, renal cell, immunotherapy, therapeutics
Asia Pac J Clin Oncol20260
Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
neoplasms, prostate, prostate-specific antigen, prostatic neoplasms
J Clin Oncol Top journal20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 1

By phase:

Phase 2 8
Phase 3 8
Phase 1/Phase 2 6
Phase 1 2
Phase 2/Phase 3 1

By status:

Completed 11
Active not recruiting 10
Recruiting 3
Unknown 1

By type:

Interventional 25

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 4
multicentric5to9 2
multicentricup10 16

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration Sensitive Prostate Cancer Receiving Physician s Choice New Hormonal Agents
NCT06120491 — neoplasms, abiraterone acetate, prostate, acetates, prostatic neoplasms, castration, men
Phase 3Active not recruiting2023
EValuation of radIOLigand Treatment in mEn With Metastatic Castration resistant Prostate Cancer With 161Tb Tb PSMA I T
NCT05521412 — safety, neoplasms, prostate, prostatic neoplasms, castration, therapeutics
Phase 1/Phase 2Recruiting2022
Combination of Radium 223 and Lutetium 177 PSMA I T in Men with Metastatic Castration Resistant Prostate Cancer
NCT05383079 — neoplasms, prostate, prostatic neoplasms, maximum tolerated dose, castration, men
Phase 1/Phase 2Active not recruiting2022
Cabazitaxel in Combination With 177Lu PSMA 617 in Metastatic Castration resistant Prostate Cancer
NCT05340374 — cells, mitosis, docetaxel, pharmaceutical preparations, neoplasms, radiopharmaceuticals, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, apoptosis, tissues, microtubules, cell death, chemotherapy, small molecules
Phase 1/Phase 2Recruiting2022
NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
NCT05024318 — radiotherapy, cells, nephrectomy, kidney, carcinoma, renal cell, carcinoma
Phase 2Recruiting2022

LeadR Networks

Main global connection map